Schmidt, Stefan R. text bibliography Electronic books. Electronic books. nju Hoboken, New Jersey John Wiley & Sons ©2013 2013 monographic eng

electronic resource

1 online resource. The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protei. pt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm. edited by Stefan R. Schmidt. Includes bibliographical references and index. Biopharmaceutics Pharmaceutical biotechnology Drug carriers Immunotoxins Therapeutic use Protein engineering Recombinant fusion proteins Therapeutic use MEDICAL Pharmacology Biopharmaceutics Pharmaceutical biotechnology Recombinant Fusion Proteins therapeutic use Drug Carriers Immunotoxins pharmacokinetics Immunotoxins therapeutic use Protein Engineering Recombinant Fusion Proteins pharmacokinetics RM301.4 .F87 2013 615.7 QU 450 Hoboken, N.J. : John Wiley & Sons, ©2013 (DLC) 2012039440 9781118354582 1118354583 9781118354575 1118354575 9781118354568 1118354567 9781118354599 1118354591 9781299241954 1299241956 2012040270 http://onlinelibrary.wiley.com/book/10.1002/9781118354599 http://onlinelibrary.wiley.com/book/10.1002/9781118354599 DLC 121002 20171113131232.0 ocn811850420 eng